EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results

EyePoint Pharmaceuticals marked a major win Monday, with Phase II results of its anti-VEGF therapy for wet age-related macular degeneration showing comparable results to Regeneron’s Eylea on a less-frequent dosing regimen.